REMARKS

In response to the restriction requirement, applicants elect Group I (claims 1-9 and 11), drawn to modified allergens, with traverse.

The traverse is based on the fact that the instant case is a National Phase application of a PCT application, and thus must be restricted according to PCT Rules. Rule 1.475 states that a product (in this case, the claims of Group I), a method of making that product (in this case, the methods of Group III, which it appears should be claims 13 and 14, rather than claims 11 and 13, as stated by the Examiner) must be examined together. The special technical feature of the invention - the claimed modified allergens - is the same for all three groups, and thus constitutes unity of invention. The restriction requirement should be withdrawn.

Claims 13 and 14 have been amended to place them in a form more consistent with U.S. practice. The amendments were not made for purposes of patentability and do not narrow the scope of the claims.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

Anthony J. Zelano
Atty. Reg. No. 27,969
Attorney/Agent for Applicant(s)

Nancy J. Axelrod
Registration No. 44,014
Patent Agent

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Filed: January 18, 2002

K:\Merck\2034\REPLY.doc

VERSION WITH MARKINGS TO SHOW CHANGES MADE

13. (Twice Amended) ~~Use of the modified recombinant allergens and/or one of their physiologically harmless salts or solvates according to Claim 1 for preparing a pharmaceutical for the~~ A method of immunospecific therapy (hyposensitization) of allergies, comprising administering to a patient in need thereof a pharmaceutical composition comprising a modified recombinant allergen according to claim 1 and a pharmaceutically acceptable carrier.

14. (Twice Amended) ~~Use of the modified recombinant allergens according to Claim 1 for~~ A method of ~~the~~ immunospecific therapy (hyposensitization) of allergies, comprising administering to a patient in need thereof a modified recombinant allergen according to claim 1.